Concluding a four-month search for Britt Meelby Jensen’s replacement, Zealand Pharma has wooed top Alnylam exec Emmanuel Dulac to take the helm as its new CEO.
Dulac’s most recent role was chief commercial officer at Alnylam, where he was brought in to build a global commercial infrastructure in two years before the biotech notched a long-awaited approval for its groundbreaking RNAi medicine.
That job took him to Basel, Switzerland, with frequent trips to the Boston area. Adding that to his previous stints at Novartis and Shire as well as board seat at Proteostasis, Dulac brings years of experience working in both Europe and North America.
All that will come in handy as Copenhagen-based Zealand puts a foot down in the US. A Nasdaq biotech class of 2017, Zealand has a pipeline of peptide-based medicines that it’s pushing in orphan or rare indications.More Peer Review
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription